Chinese pharma sales, other industry data

6 February 2001

Sales by Chinese pharmaceutical companies increased 21.8% overall to avalue of $4 billion in the first quarter of 2000, compared with the like, year-earlier period, and industry profits advanced 26.9% to $238.8 million, according to figures from the State Economic Commission and the State Statistical Bureau, reported by Chinese Medical News.

Sales in the drug trading sector grew 12.5% to $4.3 billion in the period, while exports rose 17.8% to $838 million, although overseas sales of chemical formulations fell 29.3%, notes CMN.

It is also reported that 490 varieties of imported drugs were used in China during 1999, and that 1,408 New Drug Certificates were granted by the authorities during the year, covering a total of 600 products. 697 of these NDCs related to western medicines, while 224 were for traditional Chinese medicines, 118 related to biological drugs and 369 were for generics.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight